International Study to Develop the AJCCUICC TNM Version-Ten Staging System for Nasopharyngeal Cancer Using Clinical and Molecular Data for Improved Treatment Guidance

What this Trial Is About

Researchers are conducting an international, multicenter, prospective observational study to improve the staging and prediction of treatment outcomes for nasopharyngeal carcinoma NPC. This study aims to enhance the current AJCCUICC TNM Version-Nine staging system by incorporating anatomical parameters and integrating non-anatomical factors and molecular biomarkers like Epstein-Barr virus DNA levels. The study includes patients from both endemic and non-endemic regions to ensure the staging system is globally applicable and to provide detailed data for personalized treatment decisions. All patients enrolled will receive diagnosis and treatment according to the standard clinical practices at their respective participating centers. Patients diagnosed with NPC between October 2025 and September 2026 will be recruited and followed for five years. During this period, detailed information on clinical characteristics, imaging, molecular markers, treatment, and outcomes will be collected to analyze survival rates and patterns of treatment failure. Participants will undergo standard clinical evaluations, with experienced radiologists and oncologists assessing disease extent. Clinical outcomes, including overall survival and different types of treatment failure, will be recorded throughout the five-year follow-up. This comprehensive data collection aims to develop an improved TNM staging system to better stratify patient risk and guide personalized treatment strategies worldwide.

International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer